TouchIMMUNOLOGY were delighted to talk with Professor Tonia Vincent (Centre for Osteoarthritis Pathogenesis, University of Oxford, Oxford, UK) around her presentation titled ‘OA: New Horizons for Therapy‘, which was presented at the ACR Convergence, 3-9 November 2021.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
Questions
- Could you tell us a little about canakinumab and its promise in the treatment of osteoarthritis (OA)? (0:15)
- What other OA drugs have shown positive clinical trial data in the last year? (2:47)
- Following the FDA’s rejection of tanezumab, what is the next step for this drug in OA? (5:15)
Disclosures: Tonia Vincent discloses ad hoc consultancy for Benevolent AI and academic support for STEpUP OA from: Novartis, Fidia, Galapagos, Biosplice, and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
